Long-Term Results of Dexell Endoscopic Treatment of Vesicoureteral Reflux: An Option for the Management of Recurrent Urinary Tract Infection

No Thumbnail Available
Journal Title
Journal ISSN
Volume Title
Background: Recurrent urinary tract infection (UTI) due to vesicoureteral reflux (VUR) is common in Iraq. Endoscopic treatment of VUR is used with advantages over antibiotic prophylaxis and ureteral reimplantation. Objectives: This study was performed to assess the efficacy of a new agent, Dexell, for treating patients with VUR and its ability to manage recurrent UTI. Materials and Methods: This research was a prospective study recruiting 156 patients with VUR treated by endoscopic subureteric injection of Dexell. Results: VUR were unilateral in 87 cases and bilateral in 69 cases. VUR grades II-V were 18.7%, 28%, 32%, and 21.3%, respectively. The success rates were 64% after the first injection, 82.7% after second injection, and 93.3% after third injection. All patients with grades II and III were resolved completely while the success rates in higher grades were 91.7% for grade IV and 87.5% for grade V. No significant difference was noted between males and females regarding the success rate of endoscopic treatment (92% vs 91.6%, P > 0.05). Recurrent UTI did not occur throughout the study period after the operation. Conclusions: Cystoscopic injection of Dexell is an effective method for treating patients with VUR. It is a safe day case procedure that can prevent recurrent UTI in patients with VUR.